PHF-tau Inhibitors
1 drugsAbout PHF-tau
PHF-tau, or paired helical filament tau, is a form of aggregated tau protein found in neurofibrillary tangles, which disrupt neuronal function and contribute to cognitive decline in diseases like Alzheimer's.
PHF-tau is a therapeutic target in the CNS to modify disease progression in devastating conditions like Alzheimer's, but there is currently no genetic evidence directly linking PHF-tau to specific diseases.
There is one FDA-approved drug, TAUVID, that targets PHF-tau, with a small molecule modality. AVID Radiopharmaceuticals Inc. is the only company with an approved drug for this target.
Top PHF-tau Drugs
AVID Radiopharmaceuticals Inc. is the only company with an approved drug targeting PHF-tau.
The lack of competition presents an opportunity for new entrants, but also indicates potential challenges in the target's validation.
PHF-tau Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PHF-tau, using small molecule modality.
Exploring alternative modalities like antibodies or gene therapies could provide a competitive advantage.
PHF-tau Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PHF-tau. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
PHF-tau Drug Approval Timeline (2020 - 2020)
The first and most recent drug approval for PHF-tau was TAUVID in 2020.
The recent approval and lack of subsequent drugs suggest an emerging but not yet saturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PHF-tau. A trial counts if an approved drug acting on PHF-tau is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.